NICE Guidance Supports Olaparib Use in BRCA-Mutant Breast, Prostate Cancer
The National Institute for Health and Care Excellence announced final draft guidance recommending the PARP inhibitor olaparib for patients with HER2-negative, high-risk early breast cancer harboring a BRCA1/2 mutation, as well as for those with previously treated hormone-relapsed metastatic prostate cancer with a BRCA1/2 mutation.
Helen Knight Olympia Clinical Trial Steering Committee National Institute For Health National Health Service National Institute Care Excellence
Source: onclive.com